|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Auersperg N: Ovarian surface epithelium as
a source of ovarian cancers: Unwarranted speculation or
evidence-based hypothesis? Gynecol Oncol. 130:246–251. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Holschneider CH and Berek JS: Ovarian
cancer: Epidemiology, biology, and prognostic factors. Semin Surg
Oncol. 19:3–10. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marsden DE, Friedlander M and Hacker NF:
Current management of epithelial ovarian carcinoma: A review. Semin
Surg Oncol. 19:11–19. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lengyel E: Ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shi Y and Whetstine JR: Dynamic regulation
of histone lysine methylation by demethylases. Mol Cell. 25:1–14.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Klose RJ and Zhang Y: Regulation of
histone methylation by demethylimination and demethylation. Nat Rev
Mol Cell Biol. 8:307–318. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Faundes V, Newman WG, Bernardini L, Canham
N, Clayton-Smith J, Dallapiccola B, Davies SJ, Demos MK, Goldman A,
Gill H, et al: Histone lysine methylases and demethylases in the
landscape of human developmental disorders. Am J Hum Genet.
102:175–187. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tsukada Y, Fang J, Erdjument-Bromage H,
Warren ME, Borchers CH, Tempst P and Zhang Y: Histone demethylation
by a family of JmjC domain-containing proteins. Nature.
439:811–816. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wagner KW, Alam H, Dhar SS, Giri U, Li N,
Wei Y, Giri D, Cascone T, Kim JH, Ye Y, et al: KDM2A promotes lung
tumorigenesis by epigenetically enhancing ERK1/2 signaling. J Clin
Invest. 123:5231–5246. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nalla AK, Williams TF, Collins CP, Rae DT
and Trobridge GD: Lentiviral vector-mediated insertional
mutagenesis screen identifies genes that influence androgen
independent prostate cancer progression and predict clinical
outcome. Mol Carcinog. 55:1761–1771. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cao LL, Du C, Liu H, Pei L, Qin L, Jia M
and Wang H: Lysine-specific demethylase 2A expression is associated
with cell growth and cyclin D1 expression in colorectal
adenocarcinoma. Int J Biol Markers. 1:17246008187640692018.
|
|
14
|
Chen JY, Luo CW, Lai YS, Wu CC and Hung
WC: Lysine demethylase KDM2A inhibits TET2 to promote DNA
methylation and silencing of tumor suppressor genes in breast
cancer. Oncogenesis. 6:e3692017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kong Y, Zou S, Yang F, Xu X, Bu W, Jia J
and Liu Z: RUNX3-mediated up-regulation of miR-29b suppresses the
proliferation and migration of gastric cancer cells by targeting
KDM2A. Cancer Lett. 381:138–148. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu L, Li Q, Wong SH, Huang M, Klein BJ,
Shen J, Ikenouye L, Onishi M, Schneidawind D, Buechele C, et al:
ASH1L links histone H3 lysine 36 dimethylation to MLL leukemia.
Cancer Discov. 6:770–783. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen JY, Li CF, Chu PY, Lai YS, Chen CH,
Jiang SS, Hou MF and Hung WC: Lysine demethylase 2A promotes
stemness and angiogenesis of breast cancer by upregulating Jagged1.
Oncotarget. 7:27689–27710. 2016.PubMed/NCBI
|
|
18
|
Bowen NJ, Walker LD, Matyunina LV, Logani
S, Totten KA, Benigno BB and McDonald JF: Gene expression profiling
supports the hypothesis that human ovarian surface epithelia are
multipotent and capable of serving as ovarian cancer initiating
cells. BMC Med Genomics. 2:712009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ito K and Murphy D: Application of ggplot2
to Pharmacometric Graphics. CPT Pharmacometrics Syst Pharmacol.
2:e792013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hu J, Meng Y, Zhang Z, Yan Q, Jiang X, Lv
Z and Hu L: MARCH5 RNA promotes autophagy, migration, and invasion
of ovarian cancer cells. Autophagy. 13:333–344. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Y, Wu T, Wang Y, Yang L, Hu C, Chen L
and Wu S: γ-Glutamyl cyclotransferase contributes to tumor
progression in high grade serous ovarian cancer by regulating
epithelial-mesenchymal transition via activating PI3K/AKT/mTOR
pathway. Gynecol Oncol. 149:163–172. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jiang Y, Qian X, Shen J, Wang Y, Li X, Liu
R, Xia Y, Chen Q, Peng G, Lin SY and Lu Z: Local generation of
fumarate promotes DNA repair through inhibition of histone H3
demethylation. Nat Cell Biol. 17:1158–1168. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang Y, Liu Y, Yu L, Chen J, Hou J, Cui
L, Ma D and Lu W: Histone demethylase KDM2A promotes tumor cell
growth and migration in gastric cancer. Tumour Biol. 36:271–278.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Naora H and Montell DJ: Ovarian cancer
metastasis: Integrating insights from disparate model organisms.
Nat Rev Cancer. 5:355–366. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shield K, Ackland ML, Ahmed N and Rice GE:
Multicellular spheroids in ovarian cancer metastases: Biology and
pathology. Gynecol Oncol. 113:143–148. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yilmaz M and Christofori G: EMT, the
cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev.
28:15–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kotiyal S and Bhattacharya S: Breast
cancer stem cells, EMT and therapeutic targets. Biochem Biophys Res
Commun. 453:112–116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nieto MA, Huang RY, Jackson RA and Thiery
JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
van Roy F and Berx G: The cell-cell
adhesion molecule E-cadherin. Cell Mol Life Sci. 65:3756–3788.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Christofori G and Semb H: The role of the
cell-adhesion molecule E-cadherin as a tumour-suppressor gene.
Trends Biochem Sci. 24:73–76. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Berx G, Cleton-Jansen AM, Nollet F, de
Leeuw WJ, van de Vijver M, Cornelisse C and van Roy F: E-cadherin
is a tumour/invasion suppressor gene mutated in human lobular
breast cancers. EMBO J. 14:6107–6115. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pećina-Slaus N: Tumor suppressor gene
E-cadherin and its role in normal and malignant cells. Cancer Cell
Int. 3:172003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Duran GE, Wang YC, Moisan F, Francisco EB
and Sikic BI: Decreased levels of baseline and drug-induced tubulin
polymerisation are hallmarks of resistance to taxanes in ovarian
cancer cells and are associated with epithelial-to-mesenchymal
transition. Br J Cancer. 116:1318–1328. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cheng YC, Tsao MJ, Chiu CY, Kan PC and
Chen Y: Magnolol inhibits human glioblastoma cell migration by
regulating N-cadherin. J Neuropathol Exp Neurol. 77:426–436. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu N, Peng SM, Zhan GX, Yu J, Wu WM, Gao
H, Li XF and Guo XQ: Human chorionic gonadotropin β regulates
epithelial-mesenchymal transition and metastasis in human ovarian
cancer. Oncol Rep. 38:1464–1472. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Colomiere M, Ward AC, Riley C, Trenerry
MK, Cameron-Smith D, Findlay J, Ackland L and Ahmed N: Cross talk
of signals between EGFR and IL-6R through JAK2/STAT3 mediate
epithelial-mesenchymal transition in ovarian carcinomas. Br J
Cancer. 100:134–144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cheaib B, Auguste A and Leary A: The
PI3K/Akt/mTOR pathway in ovarian cancer: Therapeutic opportunities
and challenges. Chin J Cancer. 34:4–16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sain N, Krishnan B, Ormerod MG, De Rienzo
A, Liu WM, Kaye SB, Workman P and Jackman AL: Potentiation of
paclitaxel activity by the HSP90 inhibitor
17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma
cell lines with high levels of activated AKT. Mol Cancer Ther.
5:1197–1208. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cao Y: Tumorigenesis as a process of
gradual loss of original cell identity and gain of properties of
neural precursor/progenitor cells. Cell Biosci. 7:612017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang Z, Lei A, Xu L, Chen L, Chen Y,
Zhang X, Gao Y, Yang X, Zhang M and Cao Y: Similarity in
gene-regulatory networks suggests that cancer cells share
characteristics of embryonic neural cells. J Biol Chem.
292:12842–12859. 2017. View Article : Google Scholar : PubMed/NCBI
|
